Literature DB >> 18704599

High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF.

Andreas-Claudius Hoffmann1, Ryutaro Mori, Daniel Vallbohmer, Jan Brabender, Uta Drebber, Stephan E Baldus, Ellen Klein, Mizutomo Azuma, Ralf Metzger, Christina Hoffmann, Arnulf H Hoelscher, Kathleen D Danenberg, Klaus L Prenzel, Peter V Danenberg.   

Abstract

BACKGROUND: Pancreatic cancer still has one of the worst prognoses of all cancers with a 5-year survival rate of 5%, making it necessary to find markers or gene sets that would further classify patients into different risk categories and thus allow more individually adapted multimodality treatment regimens. Especially heparanase (HPSE) has recently been discussed as a key factor in pancreatic cancer.
MATERIALS AND METHODS: Paraffin-embedded tissue samples were obtained from 41 patients with pancreatic adenocarcinoma who were scheduled for primary surgical resection. Direct quantitative real-time reverse transcriptase polymerase chain reaction (TaqMan) assays were performed in triplicates to determine HPSE, hypoxia inducible factor-1 alpha (HIF1a), platelet-derived growth factor alpha (PDGFA), heparin-binding EGF-like growth factor (HB-EGF), and basic fibroblast growth factor (bFGF) gene expression levels.
RESULTS: HPSE was significantly correlated to PDGFA (p = 0.04) and HIF1a (p = 0.04). The correlation of HIF1a to bFGF and HB-EGF was significant (p = 0.04, p = 0.02). Stepwise multiple linear regression models showed a significant independent association of HPSE with lymph node metastasis (p = 0.025) and with dedifferentiation (p = 0.042).
CONCLUSIONS: Heparanase seems to be significantly associated with lymph node metastasis (p = 0.025) as well as dedifferentiation (p = 0.042). We assume that HPSE plays a crucial role for the aggressiveness of pancreatic cancer. Larger studies including more patients seem to be warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18704599     DOI: 10.1007/s11605-008-0628-2

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  31 in total

1.  The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma.

Authors:  O N El-Assal; A Yamanoi; T Ono; H Kohno; N Nagasue
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Heparanase promotes angiogenesis through Cox-2 and HIF1alpha.

Authors:  Yoshio Naomoto; Mehmet Gunduz; Munenori Takaoka; Takaomi Okawa; Esra Gunduz; Tetsuji Nobuhisa; Masahiko Kobayashi; Yasuhiro Shirakawa; Tomoki Yamatsuji; Ryutaro Sonoda; Junji Matsuoka; Noriaki Tanaka
Journal:  Med Hypotheses       Date:  2006-08-04       Impact factor: 1.538

3.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

Authors:  D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

4.  Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival.

Authors:  Ilana Doweck; Victoria Kaplan-Cohen; Inna Naroditsky; Edmond Sabo; Neta Ilan; Israel Vlodavsky
Journal:  Neoplasia       Date:  2006-12       Impact factor: 5.715

5.  Molecular determinants of cetuximab efficacy.

Authors:  Daniel Vallböhmer; Wu Zhang; Michael Gordon; Dong Yun Yang; Jim Yun; Oliver A Press; Katrin E Rhodes; Andy E Sherrod; Syma Iqbal; Kathleen D Danenberg; Susan Groshen; Heinz-Josef Lenz
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

Review 6.  The pathology of ductal-type pancreatic carcinomas and pancreatic intraepithelial neoplasia: insights for clinicians.

Authors:  Günter Klöppel; Jutta Lüttges
Journal:  Curr Gastroenterol Rep       Date:  2004-04

7.  Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater.

Authors:  Klaus L Prenzel; Ute Warnecke-Eberz; Jan Brabender; Stephan E Baldus; Elfriede Bollschweiler; Christian A Gutschow; Uta Drebber; Arnulf H Hoelscher; Paul M Schneider
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

8.  Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer.

Authors:  M Ebert; M Yokoyama; H Friess; M S Kobrin; M W Büchler; M Korc
Journal:  Int J Cancer       Date:  1995-09-04       Impact factor: 7.396

9.  Heparanase expression in gallbladder carcinoma and its correlation to prognosis.

Authors:  Wujun Wu; Cheng'en Pan; Haibo Yu; Huilin Gong; Youli Wang
Journal:  J Gastroenterol Hepatol       Date:  2007-05-24       Impact factor: 4.029

10.  Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression.

Authors:  A Couvelard; D O'Toole; H Turley; R Leek; A Sauvanet; C Degott; P Ruszniewski; J Belghiti; A L Harris; K Gatter; F Pezzella
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

View more
  18 in total

1.  Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL.

Authors:  Yang Yang; Yongsheng Ren; Vishnu C Ramani; Li Nan; Larry J Suva; Ralph D Sanderson
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

2.  Significance of heparanase in cancer and inflammation.

Authors:  Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin
Journal:  Cancer Microenviron       Date:  2011-08-03

3.  Radiation Therapy Reduced Blood Levels of LDH, HIF-1α, and miR-210 in OSCC.

Authors:  Marcela Gonçalves de Souza; Sabrina Ferreira de Jesus; Eloá Mangabeira Santos; Emisael Stenio Batista Gomes; Arlen de Paulo Santiago Filho; Eliane Macedo Sobrinho Santos; Luiz Henrique da Silveira; Sérgio Henrique Sousa Santos; Alfredo Maurício Batista de Paula; Lucyana Conceição Farias; André Luiz Sena Guimarães
Journal:  Pathol Oncol Res       Date:  2018-11-08       Impact factor: 3.201

4.  Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma.

Authors:  Amichay Meirovitz; Esther Hermano; Immanuel Lerner; Eyal Zcharia; Claudio Pisano; Tamar Peretz; Michael Elkin
Journal:  Cancer Res       Date:  2011-03-29       Impact factor: 12.701

5.  Heparanase promotes radiation resistance of cervical cancer by upregulating hypoxia inducible factor 1.

Authors:  Jianping Li; Xin Meng; Jing Hu; Ying Zhang; Yunzhi Dang; Lichun Wei; Mei Shi
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

Review 6.  Pancreatic endocrine neoplasms: a current update on genetics and imaging.

Authors:  S Philips; S N Shah; R Vikram; S Verma; A K P Shanbhogue; S R Prasad
Journal:  Br J Radiol       Date:  2012-01-17       Impact factor: 3.039

Review 7.  Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Authors:  Israel Vlodavsky; Preeti Singh; Ilanit Boyango; Lilach Gutter-Kapon; Michael Elkin; Ralph D Sanderson; Neta Ilan
Journal:  Drug Resist Updat       Date:  2016-10-06       Impact factor: 18.500

Review 8.  Versatile role of heparanase in inflammation.

Authors:  Rachel Goldberg; Amichay Meirovitz; Nir Hirshoren; Raanan Bulvik; Adi Binder; Ariel M Rubinstein; Michael Elkin
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

9.  Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease.

Authors:  Jian Ruan; Timothy N Trotter; Li Nan; Rongcheng Luo; Amjad Javed; Ralph D Sanderson; Larry J Suva; Yang Yang
Journal:  Bone       Date:  2013-07-27       Impact factor: 4.398

Review 10.  Heparanase in inflammation and inflammation-associated cancer.

Authors:  Amichay Meirovitz; Rachel Goldberg; Adi Binder; Ariel M Rubinstein; Esther Hermano; Michael Elkin
Journal:  FEBS J       Date:  2013-03-04       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.